{"id":50543,"date":"2017-09-20T10:29:25","date_gmt":"2017-09-20T14:29:25","guid":{"rendered":"http:\/\/www.bumc.bu.edu\/busm\/?p=50543"},"modified":"2017-09-20T10:29:25","modified_gmt":"2017-09-20T14:29:25","slug":"new-study-offers-novel-treatment-strategy-for-patients-with-colon-cancer","status":"publish","type":"post","link":"https:\/\/www.bumc.bu.edu\/camed\/2017\/09\/20\/new-study-offers-novel-treatment-strategy-for-patients-with-colon-cancer\/","title":{"rendered":"New Study Offers Novel Treatment Strategy for Patients with Colon Cancer"},"content":{"rendered":"<p>Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide.\u00a0In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 (IGPR-1) which was recently identified in the same laboratory as a cell adhesion molecule.<\/p>\n<p>The new findings, reported online in <em>Oncogenesis<\/em>, shed light on how IGPR-1 contribute to colon tumor growth and drug resistance.<\/p>\n<p>To grow and survive, normal cells needs to attach to extracellular matrix (ECM). However, cancerous cells, often bypass this requirement and instead they rely on cell-cell adhesion for survival and growth. By manipulating IGPR-1 expression in colon cancer tumor, the scientists revealed that IGPR-1 by promoting tumor cell-cell adhesion plays a critical role in colon cancer. The researchers hope to propose a new treatment strategy for patients with colon cancer.<\/p>\n<p>\u201cWe demonstrate that IGPR-1 by promoting tumor cell-cell adhesion stimulates tumor growth in cell culture and in an experimental model. Blocking IGPR-1 by a specific blocking antibody and shRNA inhibited tumor growth, suggesting a significant therapeutic potential for targeting IGPR-1 in colorectal cancer \u201d explained corresponding author Nader Rahimi, PhD, associate professor of pathology &amp; laboratory Medicine at BUSM.<\/p>\n<p>The researchers also demonstrated that IGPR-1 determines the sensitivity of tumor cells to chemotherapeutic agent, doxorubicin\/Adriamycin and identified the mechanism by which IGPR-1 contributes to drug resistance in colon cancer, a major challenge associated with the treatment of this cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For the first time, researchers demonstrate that a previously uncharacterized protein is increased in colon cancer.<\/p>\n","protected":false},"author":12772,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[91,90],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts\/50543"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/users\/12772"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/comments?post=50543"}],"version-history":[{"count":3,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts\/50543\/revisions"}],"predecessor-version":[{"id":50546,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/posts\/50543\/revisions\/50546"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/media?parent=50543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/categories?post=50543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/camed\/wp-json\/wp\/v2\/tags?post=50543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}